Immunomodulatory drugs (IMiDs) are thalidomide analogues, which possess pleiotropic anti-myeloma properties including immune-modulation, anti-angiogenic, anti-inflammatory and anti-proliferative effects. Their development was facilitated by an improved understanding in myeloma (MM) biology and initiated a profound shift in the therapeutic approach towards MM. Despite the diverse effects of IMiDs in vitro, the relative contribution of each effect towards their ultimate anti-MM activity is still unclear. Based on in vitro data, it appears that anti-proliferative effects and downregulation of crucial cytokines are their most important anti-MM attributes. Although the co-stimulatory effects on T and NK cells have been heralded as a unique and i...
Although Thalidomide (Thal) does not directly induce T cell activation, it increases proliferation o...
<p>Multiple myeloma (MM) is a proliferation of tumoral plasma B cells that is still incurable. Natur...
Introduction: Impressive therapeutic progress is being made in the management of multiple myeloma (M...
Multiple myeloma (MM) is a clonal disorder of plasma cells that is considered incurable using the cu...
© 2010 Dr. Hang Ai QuachOver the last decade, the introduction of novel therapeutic agents including...
Immunomodulatory drugs (IMiDs) are effective treatments for patients with multiple myeloma. IMiDs ha...
Over the past 15 years, significant progress has been made in understanding the biology and treatmen...
© 2021 Matteo CostacurtaMultiple myeloma (MM) is an incurable plasma cell neoplasm. The incorporatio...
The design of innovative, more effective, less toxic therapy of multiple myeloma (MM) is emerging in...
Over the past two decades, the improvement in our understanding of the biology of MM and the introdu...
Although thalidomide (Thal) does not directly induce T-cell activation, it in-creases proliferation ...
Transformed plasma cells in multiple myeloma (MM) are susceptible to natural killer (NK) cell-mediat...
Background: Myelodysplastic syndromes (MDS) are common adult hematologic disorders characterized by ...
Lenalidomide is a synthetic compound derived by modifying the chemical structure of thalidomide. It ...
<p>Multiple myeloma (MM) is a proliferation of tumoral plasma B cells that is still incurable. Natur...
Although Thalidomide (Thal) does not directly induce T cell activation, it increases proliferation o...
<p>Multiple myeloma (MM) is a proliferation of tumoral plasma B cells that is still incurable. Natur...
Introduction: Impressive therapeutic progress is being made in the management of multiple myeloma (M...
Multiple myeloma (MM) is a clonal disorder of plasma cells that is considered incurable using the cu...
© 2010 Dr. Hang Ai QuachOver the last decade, the introduction of novel therapeutic agents including...
Immunomodulatory drugs (IMiDs) are effective treatments for patients with multiple myeloma. IMiDs ha...
Over the past 15 years, significant progress has been made in understanding the biology and treatmen...
© 2021 Matteo CostacurtaMultiple myeloma (MM) is an incurable plasma cell neoplasm. The incorporatio...
The design of innovative, more effective, less toxic therapy of multiple myeloma (MM) is emerging in...
Over the past two decades, the improvement in our understanding of the biology of MM and the introdu...
Although thalidomide (Thal) does not directly induce T-cell activation, it in-creases proliferation ...
Transformed plasma cells in multiple myeloma (MM) are susceptible to natural killer (NK) cell-mediat...
Background: Myelodysplastic syndromes (MDS) are common adult hematologic disorders characterized by ...
Lenalidomide is a synthetic compound derived by modifying the chemical structure of thalidomide. It ...
<p>Multiple myeloma (MM) is a proliferation of tumoral plasma B cells that is still incurable. Natur...
Although Thalidomide (Thal) does not directly induce T cell activation, it increases proliferation o...
<p>Multiple myeloma (MM) is a proliferation of tumoral plasma B cells that is still incurable. Natur...
Introduction: Impressive therapeutic progress is being made in the management of multiple myeloma (M...